We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Osteopontin as a Biomarker for Ovarian Cancer

Robert C. Wallach, MD
JAMA. 2002;287(24):3208-3210. doi:10.1001/jama.287.24.3206.
Text Size: A A A
Published online


To the Editor: The article by Dr Kim and colleagues1 raises the false hope of finding "tumor markers that could be used to detect the early stages of the disease." It is not at all clear, and certainly not proved, that advanced stage ovarian carcinoma begins as a disease confined to the ovary (stage I). Frequently, patients with disseminated disease have relatively small tumor deposits in the ovaries and the primary tumor may have been on adjacent or distant peritoneal surfaces, or there may have been a multifocal origin.2 The extreme cases are those referred to as "peritoneal carcinoma" in which the ovaries seem uninvolved or have demonstrable secondary implants only. Finding stage I ovarian carcinoma early is a laudable ambition, and sensitive and specific tumor markers may be useful in this pursuit. However, the rapid progression of the disease and the multifocal nature suggest that efforts and money would best be directed to more effective and specific treatment rather than chasing the possibility of "early" disease. Experience with the CA125 marker, which is quite useful for measuring and following advanced disease, demonstrates that the likelihood of a sensitive marker improving survival is remote or nil. Also, it is to be expected that fearful patients and physicians will request the results for the marker in inappropriate situations as they currently do for CA125.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

5 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.